CN201186106Y - Medicament treatment probe instrument in angiocarpy based on optical fiber minimal invasion - Google Patents
Medicament treatment probe instrument in angiocarpy based on optical fiber minimal invasion Download PDFInfo
- Publication number
- CN201186106Y CN201186106Y CNU2008200221146U CN200820022114U CN201186106Y CN 201186106 Y CN201186106 Y CN 201186106Y CN U2008200221146 U CNU2008200221146 U CN U2008200221146U CN 200820022114 U CN200820022114 U CN 200820022114U CN 201186106 Y CN201186106 Y CN 201186106Y
- Authority
- CN
- China
- Prior art keywords
- fiber
- cardiovascular
- optical fiber
- probe needle
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The utility model relates to a cardiovascular inner drug treatment probe needle instrument based on fiber minimally invasive, which comprises fiber, wherein the fiber at least has one, one end of the fiber is equipped with a probe needle, the outer portion of the probe needle is equipped with a porous jacket layer, fluorescence drug is coated on the inner portion of a hole of the porous jacket layer, and the other end of the fiber is connected with adjustable light source (high low energy). The cardiovascular inner drug treatment probe needle instrument utilizes a fiber light needle (which can be a plurality of beams of fibers), the probe needle adsorbs drug and protein molecular nutrients which treat cardiovascular diseases, and is inserted in a cardiovascular after solidifying, is led to aura positions through guide light fiber fluorescence in fiber beams, drug melts to be coated on the aura positions to directly treat. The cardiovascular inner drug treatment probe needle instrument is easy to operate and has low cost. Using the cardiovascular inner drug treatment probe needle instrument, some vascular diseases which are high blood viscosity, hyperlipemia, hypertension, arteriosclerosis, rhinitis, varicosity and vasculitis and the like can be directly treated using drug after tissue regeneration and organ transplantation.
Description
Technical field
This utility model relates to a kind of medical appurtenance, and is especially a kind of based on Drug therapy probe instrument in the cardiovascular of optical fiber Wicresoft.
Background technology
At present cardiovascular disease is the highest a kind of of sickness rate in the mortality rate disease with high, thereby to be known as be human " No.1 killer ", and therefore causes the great attention of countries in the world hygiene department and medical worker.
Cardiovascular laser therapy technology, from the eighties from the beginning of, begin fiber guides laser beam on probation in the world and get through block part to intra-arterial, this technology is called laser angioplasty, this technology one side will melt the thrombosis in the blood vessel effectively; Must prevent again that on the other hand unnecessary laser energy from punching the coronary artery tube wall, difficulty is big in the practical application control.Another kind is an Intravascular Low Level Laser Irradiation Therapy, and this method is proposed the seventies by former Soviet Union scholar the earliest, and is applied to clinical the end of the eighties.Using maximum so far is the helium-neon laser of wavelength 632.8 nanometers, and output is the milliwatt magnitude, and optical fiber " laser accunputure " injects blood vessel, laser beam is imported and irradiation of blood by optical fiber, utilize low energy laser blood illuminator technology, irradiation of blood can produce some very profound biological effects.For example, the rheological property of blood is changed, thereby improve microcirculation in human body; Promote the body oxygen metabolism, improve the tissue oxygen utilization rate, and then strengthen the function of hypoxic-ischemic cardiac muscle.In the Intravascular Low Level Laser Irradiation Therapy practical application and bad, need accurately to control the energy of laser simultaneously, difficulty is big, intravascular irradiation for a long time in addition, and patient is difficult to stand.
Summary of the invention
This utility model is for overcoming above-mentioned the deficiencies in the prior art, provide a kind of simple in structure, easy to use, therapeutic effect is good based on Drug therapy probe instrument in the cardiovascular of optical fiber Wicresoft.
The purpose of this utility model is to adopt following technical proposals to realize: a kind of based on Drug therapy probe instrument in the cardiovascular of optical fiber Wicresoft, comprise and pass light optical fiber, described optical fiber has one at least, one end of optical fiber is provided with probe, the outside of probe is provided with the porous jacket layer, and the porous jacket layer is coated with medicine in the hole; The other end of optical fiber connects tunable light source.
Described porous jacket layer is provided with the hole of some absorption medicines.
Described light source is high low energy light source.
This utility model utilizes optical fiber laser accunputure (multiple beams of optical fiber), the medicine of syringe needle adsorbing therapy cardiovascular disease and protein molecular nutrient substance, after solidifying, in the insertion cardiovascular, be directed to the aura place by light-conductive optic fibre fluorescence in the fibre bundle, the medicine thawing is coated in the aura affected part, directly treatment, simple, cost is low.If this utility model simple optical fiber can coated medicament; Logical light in the multifiber, other capture.Utilize this utility model can be to direct Drug therapy after some angiopathy tissue regenerations, the organ transplantations such as high blood viscosity, hyperlipemia, hypertension, arteriosclerosis, rhinitis, varicosis, vasculitis.
Description of drawings
Fig. 1 is this utility model structural representation;
Wherein 1. optical fiber, 2. probe, 3. porous jacket layer, 4. medicine, 5. light source.
The specific embodiment
Below in conjunction with drawings and Examples this utility model is further specified.
Among Fig. 1, an end of optical fiber 1 is provided with probe 2, and the outside of probe 2 is provided with porous jacket layer 3, and porous jacket layer 3 is provided with the hole of some absorption medicines, is coated with fluorescence medicine 4 in the porous jacket layer 3; The other end of optical fiber 1 connects high low energy light source 5.
This utility model utilizes multiple beams of optical fiber 1, and the medicine of syringe needle adsorbing therapy cardiovascular disease and protein molecular nutrient substance are after solidifying, in the insertion cardiovascular, be directed to the aura place by light-conductive optic fibre fluorescence in the fibre bundle, medicine 4 thawings are coated in the aura affected part, directly treatment, simple, cost is low.
Utilize this utility model can be to direct Drug therapy after some angiopathy tissue regenerations, the organ transplantations such as high blood viscosity, hyperlipemia, hypertension, arteriosclerosis, rhinitis, varicosis, vasculitis.As, varicosis → optical fiber light coagulates art: intravenous optical fiber light coagulates art optical fiber intravascular angiography catheter is entered in the great saphenous vein blood vessel, utilize 810 nanometer light to coagulate and accurately damage blood vessel, tunica intima is because photo-thermal effect is destroyed, thereby make vessel sealing and fibrosis takes place, thereby reach the purpose of treatment.Along with the continuous development of Minimally Invasive Surgical Technology, intravenous optical fiber light coagulates art and was updated to for the 4th generation, and is reliable more and extensive on curative effect and range of application.
Claims (3)
1. one kind based on Drug therapy probe instrument in the cardiovascular of optical fiber Wicresoft, comprises passing light optical fiber, and it is characterized in that: described optical fiber has one at least, and an end of optical fiber is provided with probe, and the outside of probe is provided with the porous jacket layer, is coated with medicine in the porous jacket layer; The other end of optical fiber connects tunable light source.
2. according to claim 1 based on Drug therapy probe instrument in the cardiovascular of optical fiber Wicresoft, it is characterized in that: described porous jacket layer is provided with some holes of absorption medicine.
3. according to claim 1 based on Drug therapy probe instrument in the cardiovascular of optical fiber Wicresoft, it is characterized in that: described light source is high low energy light source.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2008200221146U CN201186106Y (en) | 2008-05-09 | 2008-05-09 | Medicament treatment probe instrument in angiocarpy based on optical fiber minimal invasion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2008200221146U CN201186106Y (en) | 2008-05-09 | 2008-05-09 | Medicament treatment probe instrument in angiocarpy based on optical fiber minimal invasion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201186106Y true CN201186106Y (en) | 2009-01-28 |
Family
ID=40309121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNU2008200221146U Expired - Fee Related CN201186106Y (en) | 2008-05-09 | 2008-05-09 | Medicament treatment probe instrument in angiocarpy based on optical fiber minimal invasion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201186106Y (en) |
-
2008
- 2008-05-09 CN CNU2008200221146U patent/CN201186106Y/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU572107B2 (en) | Photoradiation catheter and method of treating artherosclerosis | |
| US4773899A (en) | Method of treatment of artherosclerosis and balloon catheter the same | |
| US7616989B2 (en) | Manufacturing methods for an apparatus for the controllable modification of compound concentration in a tube | |
| USRE34544E (en) | Method of treatment of artherosclerosis and balloon catheter the same | |
| WO2004012589A3 (en) | Catheter for diagnosis and treatment of diseased vessels | |
| WO2004012805A3 (en) | Light delivery catheter | |
| US20080275432A1 (en) | Photodynamic foam composition and sclerosis treatment | |
| JP5759367B2 (en) | Percutaneous vascular treatment method and apparatus | |
| CN114732516A (en) | Multifunctional laser catheter for ablating thrombus and plaque in blood vessel and inhibiting restenosis | |
| CN201186106Y (en) | Medicament treatment probe instrument in angiocarpy based on optical fiber minimal invasion | |
| CN201200610Y (en) | Acupuncture device | |
| Zharov et al. | Laser combined medical technologies from Russia | |
| CN201453778U (en) | Laser-driven needle-free injection device | |
| CN109009346B (en) | Zero incision varicose vein treatment device | |
| CN101934106B (en) | Laser driving needleless injection system | |
| JP4793651B2 (en) | Sheath removal hole closing device using laser welding | |
| CN108938137A (en) | Transurethral bladder communication apparatus | |
| CN216986087U (en) | Sleeve suitable for accurate photodynamic therapy | |
| CN2411017Y (en) | Laser acupuncture needle | |
| CN215960250U (en) | Blood vessel closing device | |
| RU2295365C1 (en) | Laser therapy method for treating benign prostate hyperplasia cases | |
| CN2412589Y (en) | Puncture trocar | |
| US20220133408A1 (en) | Hydrogel co-injection and real-time opto-electromagnetic modification device for tunable in-vivo delivery | |
| RU119240U1 (en) | DEVICE FOR PHOTODYNAMIC THERAPY OF HYPERPLASIA OF THE PROSTATE | |
| CN2538375Y (en) | Laser illumination therapeutic apparatus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090128 |